Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Scarfò, L, Chatzikonstantinou, T, Rigolin, GM, Quaresmini, G, Motta, M, Vitale, C, Garcia-Marco, JA, Hernández-Rivas, JÁ, Mirás, F, Baile, M, Marquet, J, Niemann, CU, Reda, G, Munir, T, Gimeno, E, Marchetti, M, Quaglia, FM, Varettoni, M, Delgado, J, Iyengar, S, Janssens, A, Marasca, R, Ferrari, A, Cuéllar-García, C, Itchaki, G, Špaček, M, De Paoli, L, Laurenti, L, Levin, M-D, Lista, E, Mauro, FR, Šimkovič, M, Van Der Spek, E, Vandenberghe, E, Trentin, L, Wasik-Szczepanek, E, Ruchlemer, R, Bron, D, De Paolis, MR, Del Poeta, G, Farina, L, Foglietta, M, Gentile, M, Herishanu, Y, Herold, T, Jaksic, O, Kater, AP, Kersting, S, Malerba, L, Orsucci, L, Popov, VM, Sportoletti, P, Yassin, M, Pocali, B, Barna, G, Chiarenza, A, Dos Santos, G, Nikitin, E, Andres, M, Dimou, M, Doubek, M, Enrico, A, Hakobyan, Y, Kalashnikova, O, Ortiz Pareja, M, Papaioannou, M, Rossi, D, Shah, N, Shrestha, A, Stanca, O, Stavroyianni, N, Strugov, V, Tam, C, Zdrenghea, M, Coscia, M, Stamatopoulos, K, Rossi, G, Rambaldi, A, Montserrat, E, Foà, R, Cuneo, A & Ghia, P 2020, 'COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus', Leukemia, vol. 34, no. 9, pp. 2354-2363. https://doi.org/10.1038/s41375-020-0959-x

APA

Scarfò, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernández-Rivas, J. Á., Mirás, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., ... Ghia, P. (2020). COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 34(9), 2354-2363. https://doi.org/10.1038/s41375-020-0959-x

CBE

Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin M-D, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. 2020. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 34(9):2354-2363. https://doi.org/10.1038/s41375-020-0959-x

MLA

Vancouver

Author

Scarfò, Lydia ; Chatzikonstantinou, Thomas ; Rigolin, Gian Matteo ; Quaresmini, Giulia ; Motta, Marina ; Vitale, Candida ; Garcia-Marco, Jose Antonio ; Hernández-Rivas, José Ángel ; Mirás, Fatima ; Baile, Mónica ; Marquet, Juan ; Niemann, Carsten U ; Reda, Gianluigi ; Munir, Talha ; Gimeno, Eva ; Marchetti, Monia ; Quaglia, Francesca Maria ; Varettoni, Marzia ; Delgado, Julio ; Iyengar, Sunil ; Janssens, Ann ; Marasca, Roberto ; Ferrari, Angela ; Cuéllar-García, Carolina ; Itchaki, Gilad ; Špaček, Martin ; De Paoli, Lorenzo ; Laurenti, Luca ; Levin, Mark-David ; Lista, Enrico ; Mauro, Francesca R ; Šimkovič, Martin ; Van Der Spek, Ellen ; Vandenberghe, Elisabeth ; Trentin, Livio ; Wasik-Szczepanek, Ewa ; Ruchlemer, Rosa ; Bron, Dominique ; De Paolis, Maria Rosaria ; Del Poeta, Giovanni ; Farina, Lucia ; Foglietta, Myriam ; Gentile, Massimo ; Herishanu, Yair ; Herold, Tobias ; Jaksic, Ozren ; Kater, Arnon P ; Kersting, Sabina ; Malerba, Lara ; Orsucci, Lorella ; Popov, Viola Maria ; Sportoletti, Paolo ; Yassin, Mohamed ; Pocali, Barbara ; Barna, Gabor ; Chiarenza, Annalisa ; Dos Santos, Gimena ; Nikitin, Eugene ; Andres, Martin ; Dimou, Maria ; Doubek, Michael ; Enrico, Alicia ; Hakobyan, Yervand ; Kalashnikova, Olga ; Ortiz Pareja, Macarena ; Papaioannou, Maria ; Rossi, Davide ; Shah, Nimish ; Shrestha, Amit ; Stanca, Oana ; Stavroyianni, Niki ; Strugov, Vladimir ; Tam, Constantine ; Zdrenghea, Mihnea ; Coscia, Marta ; Stamatopoulos, Kostas ; Rossi, Giuseppe ; Rambaldi, Alessandro ; Montserrat, Emili' ; Foà, Robin ; Cuneo, Antonio ; Ghia, Paolo. / COVID-19 severity and mortality in patients with chronic lymphocytic leukemia : a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. In: Leukemia. 2020 ; Vol. 34, No. 9. pp. 2354-2363.

Bibtex

@article{aa498a8b6f11446f8fba3fda9856c1c9,
title = "COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus",
abstract = "Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.",
keywords = "Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology, Betacoronavirus, COVID-19, Comorbidity, Coronavirus Infections/diagnosis, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell/complications, Male, Middle Aged, Pandemics, Pneumonia, Viral/diagnosis, Prognosis, Protein Kinase Inhibitors/pharmacology, Pyrazoles/pharmacology, Pyrimidines/pharmacology, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Surveys and Questionnaires",
author = "Lydia Scarf{\`o} and Thomas Chatzikonstantinou and Rigolin, {Gian Matteo} and Giulia Quaresmini and Marina Motta and Candida Vitale and Garcia-Marco, {Jose Antonio} and Hern{\'a}ndez-Rivas, {Jos{\'e} {\'A}ngel} and Fatima Mir{\'a}s and M{\'o}nica Baile and Juan Marquet and Niemann, {Carsten U} and Gianluigi Reda and Talha Munir and Eva Gimeno and Monia Marchetti and Quaglia, {Francesca Maria} and Marzia Varettoni and Julio Delgado and Sunil Iyengar and Ann Janssens and Roberto Marasca and Angela Ferrari and Carolina Cu{\'e}llar-Garc{\'i}a and Gilad Itchaki and Martin {\v S}pa{\v c}ek and {De Paoli}, Lorenzo and Luca Laurenti and Mark-David Levin and Enrico Lista and Mauro, {Francesca R} and Martin {\v S}imkovi{\v c} and {Van Der Spek}, Ellen and Elisabeth Vandenberghe and Livio Trentin and Ewa Wasik-Szczepanek and Rosa Ruchlemer and Dominique Bron and {De Paolis}, {Maria Rosaria} and {Del Poeta}, Giovanni and Lucia Farina and Myriam Foglietta and Massimo Gentile and Yair Herishanu and Tobias Herold and Ozren Jaksic and Kater, {Arnon P} and Sabina Kersting and Lara Malerba and Lorella Orsucci and Popov, {Viola Maria} and Paolo Sportoletti and Mohamed Yassin and Barbara Pocali and Gabor Barna and Annalisa Chiarenza and {Dos Santos}, Gimena and Eugene Nikitin and Martin Andres and Maria Dimou and Michael Doubek and Alicia Enrico and Yervand Hakobyan and Olga Kalashnikova and {Ortiz Pareja}, Macarena and Maria Papaioannou and Davide Rossi and Nimish Shah and Amit Shrestha and Oana Stanca and Niki Stavroyianni and Vladimir Strugov and Constantine Tam and Mihnea Zdrenghea and Marta Coscia and Kostas Stamatopoulos and Giuseppe Rossi and Alessandro Rambaldi and Emili' Montserrat and Robin Fo{\`a} and Antonio Cuneo and Paolo Ghia",
year = "2020",
month = sep,
doi = "10.1038/s41375-020-0959-x",
language = "English",
volume = "34",
pages = "2354--2363",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

RIS

TY - JOUR

T1 - COVID-19 severity and mortality in patients with chronic lymphocytic leukemia

T2 - a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

AU - Scarfò, Lydia

AU - Chatzikonstantinou, Thomas

AU - Rigolin, Gian Matteo

AU - Quaresmini, Giulia

AU - Motta, Marina

AU - Vitale, Candida

AU - Garcia-Marco, Jose Antonio

AU - Hernández-Rivas, José Ángel

AU - Mirás, Fatima

AU - Baile, Mónica

AU - Marquet, Juan

AU - Niemann, Carsten U

AU - Reda, Gianluigi

AU - Munir, Talha

AU - Gimeno, Eva

AU - Marchetti, Monia

AU - Quaglia, Francesca Maria

AU - Varettoni, Marzia

AU - Delgado, Julio

AU - Iyengar, Sunil

AU - Janssens, Ann

AU - Marasca, Roberto

AU - Ferrari, Angela

AU - Cuéllar-García, Carolina

AU - Itchaki, Gilad

AU - Špaček, Martin

AU - De Paoli, Lorenzo

AU - Laurenti, Luca

AU - Levin, Mark-David

AU - Lista, Enrico

AU - Mauro, Francesca R

AU - Šimkovič, Martin

AU - Van Der Spek, Ellen

AU - Vandenberghe, Elisabeth

AU - Trentin, Livio

AU - Wasik-Szczepanek, Ewa

AU - Ruchlemer, Rosa

AU - Bron, Dominique

AU - De Paolis, Maria Rosaria

AU - Del Poeta, Giovanni

AU - Farina, Lucia

AU - Foglietta, Myriam

AU - Gentile, Massimo

AU - Herishanu, Yair

AU - Herold, Tobias

AU - Jaksic, Ozren

AU - Kater, Arnon P

AU - Kersting, Sabina

AU - Malerba, Lara

AU - Orsucci, Lorella

AU - Popov, Viola Maria

AU - Sportoletti, Paolo

AU - Yassin, Mohamed

AU - Pocali, Barbara

AU - Barna, Gabor

AU - Chiarenza, Annalisa

AU - Dos Santos, Gimena

AU - Nikitin, Eugene

AU - Andres, Martin

AU - Dimou, Maria

AU - Doubek, Michael

AU - Enrico, Alicia

AU - Hakobyan, Yervand

AU - Kalashnikova, Olga

AU - Ortiz Pareja, Macarena

AU - Papaioannou, Maria

AU - Rossi, Davide

AU - Shah, Nimish

AU - Shrestha, Amit

AU - Stanca, Oana

AU - Stavroyianni, Niki

AU - Strugov, Vladimir

AU - Tam, Constantine

AU - Zdrenghea, Mihnea

AU - Coscia, Marta

AU - Stamatopoulos, Kostas

AU - Rossi, Giuseppe

AU - Rambaldi, Alessandro

AU - Montserrat, Emili'

AU - Foà, Robin

AU - Cuneo, Antonio

AU - Ghia, Paolo

PY - 2020/9

Y1 - 2020/9

N2 - Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

AB - Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents/pharmacology

KW - Betacoronavirus

KW - COVID-19

KW - Comorbidity

KW - Coronavirus Infections/diagnosis

KW - Female

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell/complications

KW - Male

KW - Middle Aged

KW - Pandemics

KW - Pneumonia, Viral/diagnosis

KW - Prognosis

KW - Protein Kinase Inhibitors/pharmacology

KW - Pyrazoles/pharmacology

KW - Pyrimidines/pharmacology

KW - Retrospective Studies

KW - SARS-CoV-2

KW - Severity of Illness Index

KW - Surveys and Questionnaires

U2 - 10.1038/s41375-020-0959-x

DO - 10.1038/s41375-020-0959-x

M3 - Journal article

C2 - 32647324

VL - 34

SP - 2354

EP - 2363

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -

ID: 62329186